# Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis

> **NCT00586651** · PHASE2 · COMPLETED · sponsor: **Cephalon** · enrollment: 39 (actual)

## Conditions studied

- Polycythemia Vera
- Essential Thrombocytosis

## Interventions

- **DRUG:** lestaurtinib

## Key facts

- **NCT ID:** NCT00586651
- **Lead sponsor:** Cephalon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2009-10
- **Final completion:** 2010-09
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2015-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00586651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00586651, "Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00586651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*